Abstract
Erdafitinib is the first Food and Drug Administration (FDA)-approved oral pan-fibroblast growth factor receptor (FGFR) kinase inhibitor that binds to ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
